
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Strategic Investment Boosts Medical Device Distribution in Africa
Amethis, Proparco, ccap.ai and Vertice management have completed the acquisition of Vertice MedTech Holdings, positioning the company for accelerated expansion as the ...
Transforming Health: The Role of the South African Medical Research Council
South African Medical Research is driving meaningful progress in addressing the region’s most pressing health challenges. What are the priorities of the South African Medical Research Council for shaping the future of health? In a recent interview, President and CEO Ntobeko Ntusi explains how the...
Portugal Medicines Reserve: Strengthening Health System Resilience
The Portuguese Government has approved the establishment of a national and regional strategic reserve of medicines and medical devices under the Portugal Transformation, Recovery and Resilience (PTRR) plan, involving an investment of 70 million euros. This measure, announced by Prime Minister LuÃ...